{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neutralizing+Antibody&page=2", "query": { "condition": "Neutralizing Antibody", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neutralizing+Antibody&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-22T14:42:19.855Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03721510", "title": "A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV/AIDS" ], "interventions": [ { "name": "PGT121 + VRC07-523LS", "type": "BIOLOGICAL" }, { "name": "PGT121 + VRC07-523LS + PGDM1400", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "International AIDS Vaccine Initiative", "sponsor_class": "NETWORK", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 19, "start_date": "2018-12-03", "completion_date": "2022-05-02", "has_results": false, "last_update_posted_date": "2022-05-10", "last_synced_at": "2026-07-22T14:42:19.855Z", "location_count": 3, "location_summary": "Orlando, Florida • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03721510" }, { "nct_id": "NCT05627258", "title": "A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV" ], "interventions": [ { "name": "VRC-HIVMAB0115-00-AB", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 23, "start_date": "2023-01-30", "completion_date": "2024-07-17", "has_results": true, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-07-22T14:42:19.855Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05627258" }, { "nct_id": "NCT00129259", "title": "Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Anti-CD3 mAb", "type": "BIOLOGICAL" }, { "name": "Diabetes Standard of Care Treatment", "type": "OTHER" }, { "name": "Iron supplementation", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DIETARY_SUPPLEMENT" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "8 Years to 30 Years" }, "enrollment_count": 83, "start_date": "2005-09", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2017-05-22", "last_synced_at": "2026-07-22T14:42:19.855Z", "location_count": 7, "location_summary": "San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Augusta", "state": "Georgia" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00129259" }, { "nct_id": "NCT01087333", "title": "Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hairy Cell Leukemia (HCL)", "Chronic Lymphocytic Leukemia (CLL)", "Non-Hodgkins Lymphoma (NHL)", "Cutaneous T Cell Lymphoma (CTCL)", "Adult T Cell Lymphoma (ATL)" ], "interventions": [], "intervention_types": [], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1263, "start_date": "2010-03-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-07-22T14:42:19.855Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01087333" }, { "nct_id": "NCT01993706", "title": "Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infection", "Monoclonal Antibody, Human", "HIV Antibodies", "VRC01 Monoclonal Antibody", "Neutralizing Antibody" ], "interventions": [ { "name": "VRC-HIVMAB060-00-AB", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 29, "start_date": "2013-11-19", "completion_date": "2015-02-27", "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-07-22T14:42:19.855Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01993706" }, { "nct_id": "NCT03719664", "title": "Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Albuvirtide", "type": "DRUG" }, { "name": "3BNC117", "type": "DRUG" }, { "name": "Baseline ART", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Frontier Biotechnologies Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2018-12-17", "completion_date": "2022-12", "has_results": false, "last_update_posted_date": "2021-09-29", "last_synced_at": "2026-07-22T14:42:19.855Z", "location_count": 7, "location_summary": "Palm Springs, California • San Francisco, California • Ft. Pierce, Florida + 4 more", "locations": [ { "city": "Palm Springs", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03719664" }, { "nct_id": "NCT04357821", "title": "Combinatorial Therapy to Induce an HIV Remission", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV/AIDS" ], "interventions": [ { "name": "Combination Intervention", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "67 Years", "sex": "ALL", "summary": "18 Years to 67 Years" }, "enrollment_count": 11, "start_date": "2020-08-01", "completion_date": "2026-06", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-07-22T14:42:19.855Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04357821" }, { "nct_id": "NCT06071767", "title": "Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "ChAdOx1.tHIVconsv1", "type": "BIOLOGICAL" }, { "name": "ChAdOx1.HIVconsv62", "type": "BIOLOGICAL" }, { "name": "MVA.tHIVconsv3", "type": "BIOLOGICAL" }, { "name": "MVA.tHIVconsv4", "type": "BIOLOGICAL" }, { "name": "Vesatolimod (VES)", "type": "DRUG" }, { "name": "GS-5423", "type": "DRUG" }, { "name": "GS-2872", "type": "DRUG" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2024-04-01", "completion_date": "2029-08-01", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-07-22T14:42:19.855Z", "location_count": 10, "location_summary": "San Diego, California • Atlanta, Georgia • Chicago, Illinois + 7 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06071767" }, { "nct_id": "NCT06812494", "title": "A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV" ], "interventions": [ { "name": "VRC07-523LS 400mg", "type": "BIOLOGICAL" }, { "name": "PGT121.414.LS 400mg", "type": "BIOLOGICAL" }, { "name": "PGDM1400LS 400mg", "type": "BIOLOGICAL" }, { "name": "VRC07-523LS 3200mg", "type": "BIOLOGICAL" }, { "name": "PGT121.414.LS 1600mg", "type": "BIOLOGICAL" }, { "name": "PGDM1400LS 1600mg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 200, "start_date": "2025-03-07", "completion_date": "2027-09-15", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-07-22T14:42:19.855Z", "location_count": 13, "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06812494" }, { "nct_id": "NCT03837756", "title": "Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Saline", "type": "DRUG" }, { "name": "Lefitolimod", "type": "DRUG" }, { "name": "3BNC117 and 10-1074", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Aarhus", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 47, "start_date": "2019-05-06", "completion_date": "2023-05-01", "has_results": false, "last_update_posted_date": "2023-05-23", "last_synced_at": "2026-07-22T14:42:19.855Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03837756" } ] }